2021

19 October, 2021 R

Warrant holders exercise all warrants in Lipidor’s incentive program 2018/2021

STOCKHOLM, Sweden, 19 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company’s LTI 2018/2021, which was addressed… Read more

27 September, 2021 R

Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

STOCKHOLM, Sweden, September 27, 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company’s Phase III clinical study of its… Read more

24 August, 2021 R

Lipidor publishes interim report for H1 2021

STOCKHOLM, Sweden, 24[th] August 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June… Read more

06 July, 2021

Summer letter from Lipidor

STOCKHOLM, Sweden, 6 July 2021: CEO Ola Holmlund comments on the year’s progress so far and the recent commercial license agreement with the Menarini Group’s… Read more

01 July, 2021 R

Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70

STOCKHOLM, Sweden, 30 June 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which… Read more

08 June, 2021 R

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Lipidor (publ) (the “Company”) on 8 June… Read more

08 June, 2021 R

Bulletin from the annual general meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor (publ) (the “Company”) on 8 June… Read more

24 May, 2021 R

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 24 May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company” or “Lipidor”) are hereby given notice of the Extraordinary… Read more

07 May, 2021 R

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 7th May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice of the Annual… Read more

06 May, 2021 R

Lipidor publishes interim report for Q1 2021

STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January – March 2021. The… Read more

23 April, 2021 R

Lipidor publishes annual report for 2020

Stockholm, Sweden, 23 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that the company will publish its annual report for the… Read more

23 April, 2021

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and… Read more

22 April, 2021

Lipidor – update on the company’s phase III clinical trial of drug candidate AKP02 for treatment of psoriasis

Stockholm, Sweden, 22 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the… Read more

23 February, 2021 R

Lipidor AB (publ) publishes year-end report for 2020

Stockholm, 23 February 2021: Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2020. The report is available on… Read more

18 January, 2021 R

Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO[®] technology

STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics… Read more

Load more
19 October, 2021 R

Warrant holders exercise all warrants in Lipidor’s incentive program 2018/2021

STOCKHOLM, Sweden, 19 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company’s LTI 2018/2021, which was addressed… Read more

27 September, 2021 R

Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

STOCKHOLM, Sweden, September 27, 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company’s Phase III clinical study of its… Read more

24 August, 2021 R

Lipidor publishes interim report for H1 2021

STOCKHOLM, Sweden, 24[th] August 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June… Read more

01 July, 2021 R

Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70

STOCKHOLM, Sweden, 30 June 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which… Read more

08 June, 2021 R

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Lipidor (publ) (the “Company”) on 8 June… Read more

08 June, 2021 R

Bulletin from the annual general meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor (publ) (the “Company”) on 8 June… Read more

24 May, 2021 R

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 24 May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company” or “Lipidor”) are hereby given notice of the Extraordinary… Read more

07 May, 2021 R

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 7th May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice of the Annual… Read more

06 May, 2021 R

Lipidor publishes interim report for Q1 2021

STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January – March 2021. The… Read more

23 April, 2021 R

Lipidor publishes annual report for 2020

Stockholm, Sweden, 23 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that the company will publish its annual report for the… Read more

23 February, 2021 R

Lipidor AB (publ) publishes year-end report for 2020

Stockholm, 23 February 2021: Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2020. The report is available on… Read more

18 January, 2021 R

Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO[®] technology

STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics… Read more

Load more